Advanced Filters
noise

Downsview Ontario, Canada Clinical Trials

A listing of Downsview Ontario, Canada clinical trials actively recruiting patients volunteers.

Found 1,360 clinical trials
D Denise Penaloza

Optimizing Mental Health for Infants Exposed to Early Adversity: A Comparison of Breaking the Cycle and Maxxine Wright

The goal of this clinical trial is to compare the effectiveness of the Breaking the Cycle (BTC) and Maxxine Wright (MW) programs in substance-involved mothers and their children. One key difference between the two programs is that the BTC program contains an infant mental health component while the MW program …

years of age Female Phase N/A
P Principal investigator

Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post-surgical NEC and BPD±PH.

1 - 6 years of age All Phase N/A

Evaluation of the SickKids Team Obesity Management Program

In January 2010 a new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. There is a paucity of literature evaluating outcomes of children and adolescents participating in a 'clinical' setting …

12 - 18 years of age All Phase N/A
J Jonathan Ma

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence …

18 years of age Male Phase 2
S Sharaniyaa Balachandran

A2 to O Lung Transplants

Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and …

18 years of age All Phase N/A
J Joshua Bryer, BA

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

5 years of age All Phase N/A

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how …

18 years of age All Phase 2
D Dave Cescon, M.D.

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

This is a Phase 2 study for patients with resected Stage I-III HER2+ breast cancer with detected molecular residual disease (MRD+) following standard neoadjuvant and locoregional therapy delivered with curative intent. In this study Patients will be treated with neratinib in addition to their standard T-DM1 adjuvant therapy. Neratinib will …

18 years of age All Phase 2
G Gregory J Czarnota, PhD, MD

MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer

The objective of this study is to examine the safety profile and therapeutic efficacy of MRI-guided focused ultrasound microbubble therapy and radiotherapy in humans.

18 years of age All Phase 1
S Silvia Innocenti

Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease

This first-in-human clinical feasibility study will evaluate the safety and performance of the R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffold and Delivery System in patients undergoing treatment for peripheral arterial disease severe enough to have significantly reduced the blood supply to their leg. The severe reduction in blood flow causes lifestyle …

18 - 90 years of age All Phase N/A

Simplify language using AI